Article
Cell Biology
Yang Gao, Bin Chen, Ruru Wang, An Xu, Lijun Wu, Huayi Lu, Guoping Zhao
Summary: Targeting RRM1 promotes ferroptosis and affects the sensitivity of cancer cells to radiation and chemotherapy. RRM1 disrupts the activity and expression of antioxidant enzyme GPX4, leading to increased accumulation of reactive oxygen species and lipid peroxidation. Furthermore, targeting RRM1 also increases radiation-induced DNA damage and apoptotic signaling, causing crosstalk between ferroptosis and apoptosis.
CELL DEATH DISCOVERY
(2022)
Article
Medicine, Research & Experimental
Jonathan Shintaku, Wolfgang M. Pernice, Wafaa Eyaid, B. G. C. Jeevan, Zuben P. Brown, Marti Juanola-Falgarona, Javier Torres-Torronteras, Ewen W. Sommerville, Debby M. E. I. Hellebrekers, Emma L. Blakely, Alan Donaldson, Ingrid van de laar, Cheng-Shiun Leu, Ramon Marti, Joachim Frank, Kurenai Tanji, David A. Koolen, Richard J. Rodenburg, Patrick F. Chinnery, H. J. M. Smeets, Grainne S. Gorman, Penelope E. Bonnen, Robert W. Taylor, Michio Hirano
Summary: This article reports 5 patients from 4 families who presented with ptosis and ophthalmoplegia as well as multiple mtDNA deletions in muscle. The study identifies RRM1 deficiency as a cause of the disease and reveals the disruption of nucleotide synthesis.
JOURNAL OF CLINICAL INVESTIGATION
(2022)
Article
Multidisciplinary Sciences
Tomotaka Kato, Hiroaki Ono, Mikiya Fujii, Keiichi Akahoshi, Toshiro Ogura, Kosuke Ogawa, Daisuke Ban, Atsushi Kudo, Shinji Tanaka, Minoru Tanabe
Summary: High RRM1 expression in pancreatic cancer patients is associated with poorer clinical outcomes, especially in those receiving adjuvant chemotherapy. Activation of cytoplasmic RRM1 is related to cancer cell viability and drug resistance, while inhibition of RRM1 enhances the cytotoxic effects of gemcitabine for pancreatic cancer cells.
Article
Medicine, General & Internal
Jung Won Chun, Boyoung Lee, Weon Seo Park, Nayoung Han, Eun Kyung Hong, Eun Young Park, Sung Sik Han, Sang-Jae Park, Tae Hyun Kim, Woo Jin Lee, Sang Myung Woo
Summary: The study aimed to investigate the predictive and prognostic values of several biomarkers in patients with advanced biliary tract cancer treated with gemcitabine plus cisplatin. The results showed that increased intratumoral expression of RRM1 may predict poor survival in patients with this chemotherapy regimen.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Cell Biology
Liyuan Wu, Le Yin, Linxiang Ma, Jiarui Yang, Feiya Yang, Baofa Sun, Xing Nianzeng
Summary: High expression of RRM2 is associated with tumor prognosis and immunotherapy. The study reveals that high levels of RRM2 are associated with worse patient survival and immunotherapy effects through pan-cancer analysis and risk score analysis.
Article
Cell Biology
Junlei Han, Jianping Hu, Fang Sun, Hongzhi Bian, Bingxiang Tang, Xiang Fang
Summary: miR-20a suppresses NSCLC growth by inhibiting the RRM2-mediated PI3K/Akt signaling pathway, serving as a potential tumor suppressor and molecular target for NSCLC treatment.
MOLECULAR AND CELLULAR BIOCHEMISTRY
(2021)
Article
Cell Biology
Qian Liu, Lijuan Guo, Hongyan Qi, Meng Lou, Rui Wang, Boning Hai, Kailun Xu, Lijun Zhu, Yongfeng Ding, Chen Li, Lingdan Xie, Jing Shen, Xueping Xiang, Jimin Shao
Summary: The study revealed a significant correlation between the expression of MYBL2 and RRM2 in colorectal cancer (CRC), with MYBL2 playing a crucial role in CRC cell proliferation, DNA synthesis, and cell cycle progression in an RRM2-dependent manner. MYBL2 was found to directly bind to the promoter of RRM2 gene and promote its transcription during S-phase in collaboration with TAF15 and MuvB components. Combined suppression of MYBL2 and WEE1 was shown to synergistically inhibit CRC growth with low systemic toxicity in vivo, suggesting a potential novel approach for CRC treatment targeting both transcription and degradation machinery of RRM2.
CELL DEATH & DISEASE
(2021)
Article
Plant Sciences
Yongqi Cui, Meiqing He, Jie Liu, Shuang Wang, Junli Zhang, Shiyi Xie, Zhubing Hu, Siyi Guo, Dawei Yan
Summary: The maize LSC gene, encoding a large subunit of ribonucleotide reductase, plays a crucial role in dNTP synthesis, subsidiary cell development, and plant growth. The loss of subsidiary cells in the maize lsc mutant is attributed to impaired subsidiary mother cell polarization and division. In addition to the defect in subsidiary cells, the lsc mutant exhibits a dwarf morphology and pale and striped newly-grown leaves. Our findings indicate that LSC is essential for dNTP production, subsidiary mother cell polarization, subsidiary cell differentiation, and overall maize growth.
JOURNAL OF EXPERIMENTAL BOTANY
(2023)
Article
Biochemistry & Molecular Biology
Cong Wang, Ling Tian, Qiang He, Shengbin Lin, Yue Wu, Yiting Qiao, Bo Zhu, Dake Li, Guo Chen
Summary: Depletion of RNR subunit p53R2 impairs HR repair and sensitizes BRCA1/2-WT cancer cells to PARP inhibition, while loss of p53R2 leads to a decrease of HR repair factor CtIP. Casein kinase II (CK2) phosphorylates p53R2 at ser20, activating RNR for dNTPs production. Pharmacologic inhibition of CK2-mediated phosphorylation of p53R2 compromises HR repair capacity, making BRCA1/2-WT cancer cells susceptible to PARP inhibition.
Article
Anatomy & Morphology
Federica Zito Marino, Simona Baselice, Stefania Erra, Andrea Ronchi, Marco Montella, Floriana Morgillo, Giovanni Vicidomini, Mario Santini, Giuseppina Poziello, Immacolata Cozzolino, Marina Accardo, Renato Franco
Summary: This study found that coexpression of ERCC1 and RRM1 in malignant pleural mesothelioma patients is associated with poorer prognosis and may require alternative treatments. The findings suggest that ERCC1/RRM1 coexpression could serve as prognostic biomarkers for overall survival in MPM.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
(2021)
Article
Pathology
Khushbu Khetan, RanjitK Sahoo, Vandana Baloda, Shalimar, Sreenivas Vishnubhatla, Anoop Saraya, NiharRanjan Dash, Atul Sharma, Siddhartha DattaGupta, Prasenjit Das
Summary: This study found that RRM1 and ERCC1 expression levels were higher in pancreatic and cholangiocarcinoma compared to controls, with statistically significant differences. However, no correlation was observed between low and high expression of RRM1 and ERCC1 with histological markers of prognosis and overall survival in these patients. This adds to the existing controversy regarding the prognostic significance of RRM1 and ERCC1 expression in pancreatic and biliary carcinomas, beyond their therapeutic benefits.
INDIAN JOURNAL OF PATHOLOGY AND MICROBIOLOGY
(2021)
Review
Medicine, Research & Experimental
Yaqiong Zhan, Lushun Jiang, Xuehang Jin, Shuaibing Ying, Zhe Wu, Li Wang, Wei Yu, Jiepeng Tong, Li Zhang, Yan Lou, Yunqing Qiu
Summary: RRM2, the small subunit of ribonucleotide reductase, is commonly overexpressed in chemo-resistant cancer cells, mediating resistance to many chemotherapeutic drugs. Inhibition of RRM2 could enhance the anticancer activity of chemotherapy.
BIOMEDICINE & PHARMACOTHERAPY
(2021)
Article
Multidisciplinary Sciences
Ami Maruyama, Yuzo Sato, Joji Nakayama, Junko Murai, Takamasa Ishikawa, Tomoyoshi Soga, Hideki Makinoshima
Summary: This study demonstrates that RRM1 is essential for the growth of small-cell lung carcinoma cells, with its deletion inducing DNA damage response and reducing the number of cells in S phase cell cycle arrest. Additionally, RRM1 deletion causes overall changes in the metabolic profile of SCLC cells, revealing a potential link between tumor growth and the regulation of deoxyribonucleotide metabolism in SCLC.
SCIENTIFIC REPORTS
(2021)
Article
Gastroenterology & Hepatology
Jinlan Shan, Zhen Wang, Qiuping Mo, Jingpei Long, Yangfan Fan, Lu Cheng, Tao Zhang, Xiyong Liu, Xiaochen Wang
Summary: This study found a correlation between high RRM2 expression and poor prognosis in pancreatic cancer patients, and RRM2 inhibition resulted in cell cycle arrest and/or apoptosis. These findings are expected to provide a new theoretical basis for pancreatic cancer treatment.
Article
Plant Sciences
Mengjun Gu, Qiao Lu, Yi Liu, Man Cui, Yaoqi Si, Huilan Wu, Tuanyao Chai, Hong-Qing Ling
Summary: The study revealed that the large subunit of RNR, SlRNRL1, plays a crucial role in cell cycle progression, chloroplast biogenesis, and photosynthesis in tomato. Meanwhile, the homologous gene SlRNRL2 shows redundant function with SlRNRL1, and at least one of these RNRLs is necessary for tomato growth and development.
Article
Oncology
Elsa Caumette, Antonio Di Meglio, Ines Vaz-Luis, Cecile Charles, Julie Havas, Garazi Ruiz de Azua, Elise Martin, Laurence Vanlemmens, Suzette Delaloge, Sibille Everhard, Anne-Laure Martin, Asma Dhaini Merimeche, Olivier Rigal, Charles Coutant, Marion Fournier, Christelle Jouannaud, Patrick Soulie, Paul-Henri Cottu, Olivier Tredan, Gwenn Menvielle, Agnes Dumas
Summary: The return to work after breast cancer recovery is influenced by psychosocial factors, including a shift in life values towards more emphasis on private life. Clinical determinants, work-related factors, and psychosocial factors all play a role in this change. Depressive symptoms are negatively associated with this shift.
JOURNAL OF CANCER SURVIVORSHIP
(2023)
Article
Medicine, General & Internal
Cecile Charles, Aurelie Bardet, Alicia Larive, Philip Gorwood, Nicolas Ramoz, Emilie Thomas, Alain Viari, Marina Rousseau-Tsangaris, Agnes Dumas, Gwenn Menvielle, Sibille Everhard, Anne-Laure Martin, Seyive-Yvon-Arnauld Gbenou, Julie Havas, Mayssam El-Mouhebb, Antonio Di Meglio, Fabrice Andre, Barbara Pistilli, Charles Coutant, Paul Cottu, Asma Merimeche, Florence Lerebours, Olivier Tredan, Laurence Vanlemmens, Christelle Jouannaud, Christelle Levy, Ines Vaz-Luis, Stefan Michiels, Sarah Dauchy
Summary: Breast cancer diagnosis and treatment increase the risk of depression in patients, and this study aims to identify and describe different patterns of depressive symptoms in breast cancer patients during treatment and up to three years after treatment.
Article
Oncology
Davide Soldato, Julie Havas, Tracy E. Crane, Daniele Presti, Pietro Lapidari, Nathalie Rassy, Barbara Pistilli, Elise Martin, Lucia Del Mastro, Anne-Laure Martin, Alexandra Jacquet, Charles Coutant, Paul Cottu, Asma Merimeche, Florence Lerebours, Olivier Tredan, Laurence Vanlemmens, Fabrice Andre, Ines Vaz-Luis, Antonio Di Meglio
Summary: This study investigated patterns of coffee and tea consumption and their association with patient-reported outcomes and clinical outcomes among survivors of breast cancer. The study found that over one in three survivors reported high or very high consumption of coffee and/or tea, but there was no association between higher consumption and worse outcomes.
Article
Oncology
Florence Oberkampf, Maya Gutierrez, Olfa Trabelsi Grati, Emilie Le Rhun, Olivier Tredan, Isabelle Turbiez, Amir Kadi, Coraline Dubot, Sophie Taillibert, Sophie Vacher, Claire Bonneau
Summary: This study aimed to evaluate the efficacy of intrathecal trastuzumab in HER2 + BC patients with leptomeningeal metastasis. The results showed that weekly administration of 150 mg of intrathecal trastuzumab was effective in controlling neurological progression.
Article
Oncology
William Jacot, Amelie Lusque, Cecile Vicier, Audrey Mailliez, Thibault de La Motte Rouge, Luc Cabel, Christelle Levy, Anne Patsouris, Isabelle Desmoulins, Lionel Uwer, Jean-Christophe Thery, Mathieu Robain, Olivier Caron, Olivier Tredan, Thomas Filleron, Jean-Sebastien Frenel, Suzette Delaloge
Summary: In this study, the authors investigated the efficacy of platinum-based chemotherapy (PtCT) in patients with metastatic breast cancer (MBC) with and without germline BRCA1 or BRCA2 mutations. The results showed that first-line PtCT was associated with better progression-free survival (PFS) and overall survival (OS) in patients with gBRCA1/2 mutations, but not in those without mutations. These findings highlight the importance of early gBRCA1/2 testing in MBC patients.
BRITISH JOURNAL OF CANCER
(2022)
Article
Oncology
Olivier Tredan, Caroline Robert, Antoine Italiano, Fabrice Barlesi
Summary: Genome-wide testing plays a crucial role in advancing precision medicine in oncology; however, current recommendations lack specificity regarding its indications and utility for different types of cancer. To address this, a national consensus approach using a modified Delphi methodology was employed in France to provide expert opinions on the use of genome-wide testing in clinical practice. Consensus was reached through multiple rounds of rating, resulting in 24 statements agreed upon by the expert panel. While genome-wide testing was recommended for non-small cell lung cancer (NSCLC) and cancer of unknown primary (CUP), its routine use was not recommended for breast cancer and melanoma. The standardization of broad molecular screening in oncology may be facilitated by improved access to innovation in France.
BULLETIN DU CANCER
(2023)
Article
Oncology
Idlir Licaj, Elodie Coquan, Tienhan Sandrine Dabakuyo-Yonli, Sarah Dauchy, Ines Vaz Luis, Cecile Charles, Cedric Lemogne, Olivier Tredan, Laurence Vanlemmens, Christelle Jouannaud, Christelle Levy, Olivier Rigal, Marion Fournier, Thierry Petit, Florence Dalenc, Philippe Rouanet, Jerome Lemonnier, Sibille Everhard, Paul Cottu, Florence Joly
Summary: This study used the CANTO cohort to study the associations between baseline quality of life and chemotherapy dose-reductions (CDRs) or post-chemotherapy toxicities (PCTs). The results showed that baseline physical functioning and fatigue were associated with CDRs and PCTs.
Article
Oncology
Pauline Corbaux, Catherine Terret, Claire Cropet, Sylvie Chabaud, Chiara Russo, Christelle Faure, Olivier Tredan, Thomas Bachelot, Pierre-Etienne Heudel
Summary: This study aimed to examine the effect of additional chemotherapy on overall survival in patients aged 70 years or older with early breast cancer, as well as the impact of comorbidities on chemotherapy benefit. The results showed that additional chemotherapy was associated with improved overall survival, while chronic obstructive pulmonary disease and polypharmacy were associated with worse overall survival. These findings support the importance of chemotherapy considerations in elderly patients with early breast cancer.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Gisele Chvetzoff, Carole Bouleuc, Audrey Lardy-Cleaud, Pierre Saltel, Veronique Dieras, Magali Morelle, Jean-Paul Guastalla, Olivier Tredan, Paul Rebattu, Simona Pop, Isabelle Ray-Coquard, Jean-Yves Pierga, Laurent Mignot, Valerie Laurence, Valerie Bourne-Branchu, David Perol, Thomas Bachelot
Summary: This study compared the impact of early palliative care and usual oncology care on the decision for additional chemotherapy. The results showed no significant difference in the prescription rate of chemotherapy between the two groups, but the early palliative care group had less deterioration in physical functioning and improved information exchange and communication.
SUPPORTIVE CARE IN CANCER
(2023)
Article
Oncology
Houssein El Hajj, Domenico Ferraioli, Pierre Meus, Frederic Beurrier, Olivier Tredan, Isabelle Ray-Coquard, Nicolas Chopin
Summary: ObjectiveSplenectomy is performed in a significant percentage of cytoreductive surgeries for ovarian cancer. This study aimed to evaluate the impact of splenectomy on overall and disease-free survival in patients with epithelial ovarian cancer. MethodsA retrospective study was conducted on patients who underwent cytoreduction for ovarian cancer between January 2000 and December 2016. Patients were stratified into splenectomy and non-splenectomy groups, and postoperative complications and survival outcomes were analyzed. ResultsA total of 464 patients were included in the study. The splenectomy group had higher disease stages, peritoneal carcinomatosis scores, and radical surgery rates. However, there was no significant difference in complete cytoreduction rates between the two groups. Splenectomy was associated with extensive surgical procedures and increased risk of abdominopelvic lymphocele and blood transfusion. The average length of hospital stay and delay in adjuvant chemotherapy were longer in the splenectomy group. Overall and disease-free survival rates were not significantly different between the groups. ConclusionSplenectomy may be a safe procedure with no impact on overall or disease-free survival in patients with ovarian cancer. However, it is associated with longer hospital stay and delay in chemotherapy.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2023)
Article
Oncology
Khalil Hodroj, David Pellegrin, Cindy Menard, Thomas Bachelot, Thierry Durand, Philippe Toussaint, Armelle Dufresne, Benoite Mery, Olivier Tredan, Thibaut Goulvent, Pierre Heudel
Summary: This study describes the implementation of an MDT application prototype based on structured data for ABC MDT meetings, which improved the quality and confidence of clinical decisions, and could support sustained improvements to patient care.
Meeting Abstract
Oncology
Hope S. Rugo, Aditya Bardia, Frederik Marine, Javier Cortes, Peter Schmid, Delphine Loirat, Olivier Tredan, Eva Ciruelos, Florence Dalenc, Patricia Gomez Pardo, Komal L. Jhaveri, Rosemary Delaney, Olivia Fu, Lanjia Lin, Wendy Verret, Sara M. Tolaney
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Meeting Abstract
Oncology
Olivier Tredan, Damien Pouessel, Nicolas Penel, Sylvie Chabaud, Carlos A. Gomez-Roca, Diane Pannier, Mehdi Brahmi, Michel Fabbro, Marie-Eve Garcia, Delphine Larrieu-Ciron, Isabelle Laure Ray-Coquard, Marie Viala, Antoine Italiano, Philippe Alexandre Cassier, Armelle Dufresne, Valery Attignon, Isabelle Treilleux, Alain Viari, David Perol, Jean-Yves Blay
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Meeting Abstract
Oncology
Alexandra Leary, Elise Deluche, Laure Favier, Xavier Paoletti, Laura Mansi, Olivier Tredan, Lauriane Eberst, Thibault De la Motte Rouge, Florence Joly, Alain Lortholary, Benoit You, Frederik Marme, Toon Van Gorp, Anne Floquet, Jean-Sebastien Frenel
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Meeting Abstract
Oncology
Ouissam Al Jarroudi, Coralie Williams, Rita Santos, Armelle Dufresne, Valery Attignon, Anthony Ferrari, Sandrine Boyault, Laurie Tonon, Severine Tabone-Eglinger, Philippe Alexandre Cassier, Nadege Carradini, Armelle Vinceneux, Aurelie Swalduz, Alain Viari, Sylvie Chabaud, David Perol, Mohammad Afshar, Jean-Yves Blay, Olivier Tredan, Pierre Saintigny
JOURNAL OF CLINICAL ONCOLOGY
(2022)
